RJ ClariVest Capital Appreciation ETF
RJCA · ETF
About RJCA
- Issuer
- Raymond James
- Expense ratio
- 0.61%
- Assets under management
- $598.44M
- Inception
- Aug 3, 2026
- Asset class
- Equity
- Website
- rjetfs.com
RJCA key statistics
- Price-earnings ratio
- 0.00
- Average volume
- 12.00K
- Volume
- 6.22K
- Open price
- $70.66
- High today
- $71.15
- Low today
- $70.49
- 52 Week high
- $76.76
- 52 Week low
- $70.47
RJ ClariVest Capital Appreciation ETF (RJCA) at a glance
As of Oct 23, 2026, RJ ClariVest Capital Appreciation ETF (RJCA) shares are priced at $70.77, giving the company a price-to-earnings ratio of 0.00.
Today the fund has traded between $70.49 and $71.15. The current price is 0.4% above the day's low and 0.5% below its high.
Volume so far is 6.22K shares, below the average of 12.00K shares a day.
Over the past year RJ ClariVest Capital Appreciation ETF has ranged from $70.47 to $76.76, and now sits 5% of the way up that range.
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0002+0.00%
- GTVHGolden Triangle Ventures$0.0002+100.00%
- TMSHTrans Global Assets$0.0003+20.00%
- RDARRaadr$0.0002+0.00%
- GPUSHyperscale Data$0.1689+34.05%
- SEIISharing Economy International$0.0002−33.33%
- ELMEElme Communities$1.77+0.57%
- SHFSSHF Holdings$0.1324−61.39%
- XXII22nd Century Group$0.1977−8.34%
- NBNDNetBrands$0.0006−40.00%
- NVDGraniteShares ETF Trust$4.19+0.96%
- HIRUHiru$0.0006+9.09%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.49−0.10%
- CTYCITY THERAPEUTICS$20.77+0.00%
- IAMIambic Therapeutics$14.26−2.79%
- AMROAmaero$5.84+7.75%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.30+0.29%
- TRXBTRex Bio$13.81−10.90%
- RTSNRetension Pharmaceuticals$15.25−1.61%
- PAXGUPine Tree Acquisition$10.01+0.05%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.13−0.77%
- ACCVAccelevation Holdings$12.38+1.06%
- RZAIROZE AI$10.92−1.89%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.